Wed, Oct 22, 2014, 8:56 AM EDT - U.S. Markets open in 34 mins.


% | $
Quotes you view appear here for quick access.

SIGA Technologies, Inc. Message Board

  • evenu2canexcel evenu2canexcel Mar 28, 2013 7:06 AM Flag

    FDA Branded PIP as LIARS! How Soon Folks Forget? How Can Any Court Or Anyone Believe What The Company That "Murtha &

    his cronies" founded says,NWJ?

    The foll is the body of the FDA letter to PIP. GOOG "Pharmathene FDA Falsified Data" for complete letter.

    "SparVax (Recombinant Protective Antigen (rPA) Anthrax Vaccine) - Untitled Letter

    June 11, 2010


    Mr. David Wright
    President and CEO
    PharmAthene, Inc.
    One Park Place, Suite 450
    Annapolis, Md 21401

    Re: IND--b(4)-
    Bacillus anthracis Recombinant Protective Antigen 102 (rPA; E. Coli) (anthrax) vaccine -b(4)---

    Dear Mr. Wright:

    The Office of Compliance and Biologics Quality (OCBQ) in the Food and Drug Administration's (FDA's) Center for Biologics Evaluation and Research (CBER) has reviewed a Product Fact Sheet entitled “SparVax™ – Recombinant Protective Antigen (rPA) Anthrax Vaccine-Novel Second Generation Vaccine Technology” for your investigational product Bacillus anthracis Recombinant Protective Antigen 102 (rPA; E. Coli) (anthrax) vaccine -b(4)---. The product fact sheet contains false or misleading statements that represent your product as safe and effective for the purposes for which it is being investigated. This is problematic from a public health perspective because it suggests that SparVax is safe and effective when the product has not yet been approved by FDA and the promotional claims have yet to be demonstrated by substantial evidence or substantial clinical experience. As a result, these materials misbrand your investigational product in violation of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. 352(a)&(n), and 321(n), and FDA’s implementing regulations. (See 21 CFR 312.7(......."


1.460.00(0.00%)Oct 21 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.